The disclosure provides extended release pharmaceutical formulations comprising an opioid particularly buprenorphine a biocompatible organic solvent and optionally a glycol for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.